Research records indexed for Tesamorelin
This page carries 12 of the 101 records that the literature query returned for Tesamorelin, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index, and the 89 records it does not carry are not represented here. Every row resolves to a real identifier and names the study model, so no finding reads as a human claim by default. The compound page is Tesamorelin.
Indexed records
| Record | Year | Study type | Model | n as stated | What it reported |
|---|---|---|---|---|---|
| Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol pmid:42419889 | 2026 | Clinical Trial Protocol, research-article | other | Not stated | Indexed as clinical trial protocol, research-article. study model from MeSH "Humans" with no interventional publication type. subject headings: HIV Infections; Exercise Therapy; Quality Of Life; Aged, 80 And Over; Growth Hormone-Releasing Hormone. |
| Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis pmid:42538058 | 2026 | Meta-Analysis, Systematic Review | other | Not stated | Indexed as meta-analysis, systematic review. study model from MeSH "Humans" with no interventional publication type. subject headings: HIV Infections; HIV-Associated Lipodystrophy Syndrome; Growth Hormone-Releasing Hormone; Randomized Controlled Trials As Topic. |
| Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists pmid:42139091 | 2026 | Research Support, Non-U.S. Gov't, Case Reports | other | Not stated | Indexed as research support, non-u.s. gov't, case reports. study model from MeSH "Humans" with no interventional publication type. subject headings: HIV Infections; Body Mass Index; Intra-Abdominal Fat; Growth Hormone-Releasing Hormone; Obesity, Abdominal. |
| Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials pmid:41545261 | 2026 | Meta-Analysis, Systematic Review | other | Not stated | Indexed as meta-analysis, systematic review. study model from MeSH "Humans" with no interventional publication type. subject headings: Liver; HIV-Associated Lipodystrophy Syndrome; Body Composition; Intra-Abdominal Fat; Growth Hormone-Releasing Hormone. |
| Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity pmid:39813152 | 2025 | Clinical Trial, Phase II, Multicenter Study | human trial | Not stated | Indexed as clinical trial, phase ii, multicenter study. study model from MeSH "Humans" with publication type "clinical trial, phase ii". subject headings: HIV Infections; Insulin-Like Growth Factor I; Growth Hormone-Releasing Hormone; Obesity, Abdominal. |
| Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors pmid:38905488 | 2024 | Research Support, Non-U.S. Gov't, research-article | human trial | Not stated | Indexed as research support, non-u.s. gov't, research-article. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: HIV Infections; Placebos; HIV Integrase Inhibitors; Magnetic Resonance Imaging; Absorptiometry, Photon. |
| Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach pmid:34006921 | 2021 | Research Support, Non-U.S. Gov't, research-article | other | Not stated | Indexed as research support, non-u.s. gov't, research-article. study model from MeSH "Humans" with no interventional publication type. subject headings: HIV Infections; Growth Substances; Vascular Endothelial Growth Factor A; Blood Proteins; Placebos. |
| Tesamorelin improves fat quality independent of changes in fat quantity pmid:33756511 | 2021 | research-article, Research Support, N.I.H., Extramural | other | Not stated | Indexed as research-article, research support, n.i.h., extramural. study model from MeSH "Humans" with no interventional publication type. subject headings: HIV Infections; Subcutaneous Fat; Intra-Abdominal Fat; Growth Hormone-Releasing Hormone. |
| Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD pmid:32701508 | 2020 | Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as research support, n.i.h., intramural, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Liver; HIV Infections; Carcinoma, Hepatocellular; Liver Neoplasms; Hepatitis. |
| Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial pmid:31611038 | 2019 | Research Support, N.I.H., Intramural, research-article | human trial | Not stated | Indexed as research support, n.i.h., intramural, research-article. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Liver; HIV Infections; United States; Growth Hormone-Releasing Hormone; Non-Alcoholic Fatty Liver Disease. |
| The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV pmid:31237318 | 2019 | research-article, Randomized Controlled Trial | human trial | Not stated | Indexed as research-article, randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Muscle, Skeletal; HIV Infections; Canada; Growth Hormone-Releasing Hormone. |
| Tesamorelin, liver fat, and NAFLD in the setting of HIV pmid:31611037 | 2019 | Comment | other | Not stated | Indexed as comment. study model from MeSH "Humans" with no interventional publication type. subject headings: Liver; HIV Infections; Growth Hormone-Releasing Hormone; Non-Alcoholic Fatty Liver Disease. |
Where this page sits
Compound page: Tesamorelin. Class: GHRH analogues.
Retrieved 2026-10-10.
Sources
- PubChem Compound Summary for CID 16137828, Tesamorelin. PubChem, National Library of Medicine (2026). pubchem:16137828
- Drugs@FDA application register query for this compound, 1 application(s) returned: BLA022505. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:tesamorelin
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab (2010). pmid:20554713
- Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS (2008). pmid:18690162
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr (2010). pmid:20101189
- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA (2014). pmid:25038357
- Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV (2019). pmid:31611038
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.